As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...
A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...
Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious bacterial infection that is resistant to most antibiotic treatments. Healing is possible but severe infections may become chronic or ...
Please provide your email address to receive an email when new articles are posted on . Dalbavancin requires two doses 7 days apart, compared with standard 4- to 8-week therapy for S. aureus ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that causes an infection that may be resistant to many antibiotics. There are precautions you can take to avoid contracting ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An early switch to oral antibiotics in patients hospitalized ...
Bacteria from cows has shown "promising" results in treating hospital superbugs. The farmyard favorites carry a microbe that ...
Antimicrobial resistance and ecological disruption caused by broad-spectrum disinfectants have created an urgent need for precision strategies that remove harmful bacteria without damaging beneficial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback